Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm

Melanoma (Skin) Clinical Trial

Official title:

Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04695015
• Other study ID #: IRB00006761-M2020434
• Status: Not yet recruiting
• Start date: December 31, 2020
• Est. completion date: June 1, 2022

Study information

• Verified date: January 2021
• Source: Peking University
• Contact: Chun Zhang, MD/PHD
• Phone: +8618601031059
• Email: zhangc1[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to establish a standardized process for obtaining digital pathological image information of ocular tumors; use modern pathological techniques to obtain the co-expression information of multiple biomarkers in the pathological tissues of ocular tumors, and finally construct standardized digital ocular tumors with biomarkers Pathology image database.

Description:

This study is a prospective study. Patients with common and representative ocular tumors in the Department of Ophthalmology, Peking University Third Hospital, will be selected and enrolled after informed consent to collect basic clinical information, preoperative blood samples, and ocular tumors Obtain pathological image annotation data and genomics-related data from ocular tumor tissue specimens, use blood samples for genomics information analysis, provide multi-dimensional data for the development of artificial intelligence algorithms, and establish artificial intelligence-assisted image data for eye tumors Standardize the process and establish a multi-modal ocular tumor standardized database of "clinical information-tissue samples-pathological images-genomics data". The database and the diagnosis system are correlated with each other to provide optimal image data for later machine learning and related algorithm establishment, and finally the investigators will be completed the design of a new artificial intelligence-assisted diagnosis system for eye tumors.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: June 1, 2022
• Est. primary completion date: June 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Patients diagnosed with eye tumors and undergoing eye tumor surgery.

2. Patients sign informed consent for sample collection and sample transfer agreement, and can cooperate with long-term regular follow-up requirements.

Exclusion Criteria:

1. Patients who are unable to undergo tumor surgery or retain samples due to various reasons .

2. Patients who are positive for hepatitis B, HIV, and syphilis.

3. Patient compliance is poor.

Related Conditions & MeSH terms

• Basal Cell Carcinoma
• Carcinoma
• Carcinoma in Situ
• Carcinoma, Basal Cell
• Eye Neoplasms
• Melanoma
• Melanoma (Skin)
• Melanoma in Situ
• Nevus Eye
• Ocular Tumor
• Sebaceous Gland Carcinoma of the Eyelid
• Squamous Cell Carcinoma in Situ

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To compare the diagnostic accuracy of OPAL and IHC for melanoma and other tumors.	The result of OPAL automatic analysis will be compared with IHC manual counting analysis.The accuracy of the study will be declared "success" if OPAL automatic analysis meet more than 85% of the manual count for all antibody.	Up to 24 weeks.